Hepatic Encephalopathy Disease

BASICS

DESCRIPTION
Altered mental and neuromotor functioning associated with acute or chronic liver disease and/or portal systemic shunting of blood. The prominent features are mild to marked forgetfulness, impaired arousability, and a "flapping tremor" (asterixis).
  • System(s) affected: Gastrointestinal, Nervous
  • Genetics: Unknown
  • Incidence/Prevalence in USA:
    • Occurs in 1/3 of cases of cirrhosis
    • Occurs in all cases of fulminant hepatic failure
    • Present in nearly half of patients who reach the stage of liver disease requiring transplantation
  • Predominant age: Parallels that of fulminant liver disease with peak in the 40's, and cirrhosis with peak in late 50's. May occur at any age.
  • Predominant sex: Male = Female (reflecting the underlying liver disease)
SIGNS AND SYMPTOMS
  • Ages 10-60
    • Prominent signs of underlying liver disease (50%); jaundice most common, ascites second most common
    • Gastrointestinal hemorrhage with hematemesis or melena (20%)
    • Systemic infection (urinary tract or pulmonary) (20%)
    • Four stages of confusion and obtundity: (1) Forgetfulness, disturbance in nocturnal sleep, daytime drowsiness (2) Mild confusion but arousable (3) Arousable but markedly confused, limited orientation and thought content (4) Unarousable
    • Asterixis prominent in stages 2 and 3
    • Handwriting and hand coordination deteriorated in stages 1 and 2
    • Tremor prominent in stage 2
    • Psychotic thoughts infrequent
    • Reflexes symmetrically hyperactive
    • Tremor and asterixis not observed in ocular muscles
    • Mental and neurological signs change rapidly (over 6 to 12 hours)
  • Age over 60
    • Signs of underlying liver disease diminished (25%)
    • Confusion more prominent
    • Precipitating gastrointestinal hemorrhage or infection less often identified
    • Remains in stage 1 or 2 for many days
    • Progression slower
  • Age under 10
    • Signs of underlying liver disease prominent, usually fulminant hepatic failure or extremely advanced cirrhosis
    • Progression through the stages very rapid, often 6 to 12 hours
    • Precipitating cause frequently not identified
CAUSES
  • Shunting of intestinal blood through the severely diseased liver without the intervention of viable liver cells. TIPS (transjugular intrahepatic portacaval shunt), a widely used radiologically inserted shunt to lower portal pressure, produces liver encephalopathy.
  • Shunting of such blood through collateral circulation or surgically constructed portacaval shunts.
  • Thus hepatic coma may occur in extremely advanced acute liver disease (fulminant hepatic failure) or following portacaval shunting or transjugular intrahepatic portal shunt (TIPS). However, it is most common in long standing cirrhosis of the liver with spontaneous shunting of intestinal blood through collaterals.
  • Failure of liver to detoxify agents noxious to CNS, e.g., ammonia, mercaptans, fatty acids.
  • Increased aromatic and reduced branched chain amino acids in blood.
  • Precipitation of acute event, search for:
    • New overt or occult infection including spontaneous peritonitis
    • Potassium, magnesium or other electrolyte depletion
    • Use of opiate, sedative, tranquilizer, drugs
    • Gastrointestinal bleeding
RISK FACTORS
  • Infection
  • Sedative or opiate drugs
  • Electrolyte disturbance
  • Anemia
  • Gastrointestinal hemorrhage

DIAGNOSIS

LABORATORY
  • Screening blood, sputum and urine cultures to identify infection
  • Hematology to identify anemia and signs of infection
  • Standard biochemistry profile to identify hypokalemia, bilirubinemia, altered calcium status, hypomagnesemia, urea, hypoglycemia
  • Arterial blood gases
  • Liver tests to evaluate severity of underlying liver disease
  • Prothrombin and partial thromboplastin time
  • Venous ammonia (elevated in 70% of liver coma)
  • Toxicology screen for illicit drugs
  • Elevated ammonia often present
Drugs that may alter lab results:
  • Infusion of amino acid solutions may affect ammonia level
  • Opiate administration - producing severe constipation may affect ammonia level
Disorders that may alter lab results:
  • Uremia may affect ammonia level
  • Rapid and severe tissue breakdown, massive burns, trauma or infection may affect ammonia level
PATHOLOGICAL FINDINGS
  • Brain edema in 100% of fatal cases
  • Glial hypertrophy in chronic encephalopathy
SPECIAL TESTS
  • Electroencephalogram shows symmetrical slowing of basic (alpha) rhythm in common with other forms of metabolic encephalopathy
  • Visually-evoked potential specific in stages 2, 3 and 4
IMAGING
  • Useful only to rule out other diagnoses
  • CT scan of head most useful
  • Brain MRI shows increased glutamine in basal ganglia
DIAGNOSTIC PROCEDURES
  • Clinical setting and findings adequate in 80% of cases
  • Venous ammonia of great aid in patients with chronic liver disease when the clinical findings are confusing
  • EEG is useful to a limited extent, but findings are similar in other forms of metabolic encephalopathy
  • Treatment response often confirms diagnosis

TREATMENT

APPROPRIATE HEALTH CARE
  • Outpatient for stages 1 and 2 when diagnosis is clear and if recurrent can be managed satisfactorily
  • Stage 3 or 4 requires inpatient management
  • Stage 3 or 4 in fulminant hepatic failure is a strong indication for evaluation for liver transplantation. Transfer to a transplant center should be considered.
GENERAL MEASURES
  • Identify and treat vigorously precipitating causes - gastrointestinal bleed, infection, sedative drugs, or electrolyte imbalance are most common
  • Stage 2 or higher - attention to adequate fluid intake, and at least 1000 kcal (4.19 MJ) of food daily
  • Give Fleet's enema to all patients without diarrhea
  • Clumsiness and poor judgment prominent. Be sure patient has the care needed to avoid falls, cuts on broken glass, smoking burns, machinery or auto accidents.
  • Avoid sedative or opiate medications. Benzodiazepine sedatives and opiate derivatives such as Lomotil have caused liver coma.
SURGICAL MEASURES

N/A

ACTIVITY
  • As tolerated
  • Avoid driving and machinery
DIET
  • Integrate with needs of underlying liver disease
  • Lower total protein. Stage 1: avoid protein gluttony. Stage 2: limit red meat and consume small portions of all other protein foods, total protein for day 50-60 grams. Stage 3: consume 40 grams protein or vegetable protein diet (about 20 grams). Stage 4: consume 10 or fewer grams of protein. For all stages: at least 1000 kcal (4.19 MJ) ingested daily
  • As coma improves, increase dietary protein as tolerated
PATIENT EDUCATION
  • Include family in education
  • Dietitian instruction in eating lower protein diets, avoid protein bingeing
  • Avoid unnecessary sedative or antianxiety medications and opiates
  • Recognition of early signs and to get treatment promptly
  • Pamphlets (quite good for family) - American Association for the Study of Liver Diseases, 6900 Grove Road, Thorofare, NJ 08086, (609) 848-1000

FOLLOW UP

PREVENTION/AVOIDANCE
  • Avoid unessential medications, particularly opiates, sedatives
  • Avoid protein binges
POSSIBLE COMPLICATIONS
  • Recurrence
  • Stable, chronic, impaired status
  • With many recurrences, permanent basal ganglion injury (non-Wilsonian hepatolenticular degeneration)
  • Hepatorenal syndrome
  • Acute tubular necrosis
  • Bleeding
  • Disseminated intravascular coagulation
  • Bacteremia
  • Shock
EXPECTED COURSE AND PROGNOSIS
  • In acute or fulminant
    • With adequate aggressive treatment, disappears without residue or recurrence
  • In chronic liver disease
    • Coma returns
    • With each recurrence it becomes more and more difficult to treat
    • Plateau of maximum improvement shows a decrement over several years, such that the degree of improvement with treatment is less and less. Eventual 80% mortality.

MISCELLANEOUS

ASSOCIATED CONDITIONS
  • Liver disease
  • Rarely with portacaval shunt with normal liver function
AGE-RELATED FACTORS

See under Signs and symptoms

Pediatric: N/A
Geriatric: N/A
Others: N/A

PREGNANCY

May occur as a complication of pregnancy

OTHER NOTES

N/A

ABBREVIATIONS

N/A

Clinical Investigations

ROLE OF HOMOEOPATHY

Copyright © 2025 Selkey. All Rights Reserved.